Minerva Biotechnologies Revenue and Competitors
Estimated Revenue & Valuation
- Minerva Biotechnologies's estimated annual revenue is currently $4.2M per year.
- Minerva Biotechnologies's estimated revenue per employee is $155,000
Employee Data
- Minerva Biotechnologies has 27 Employees.
- Minerva Biotechnologies grew their employee count by 0% last year.
Minerva Biotechnologies's People
Name | Title | Email/Phone |
---|---|---|
1 | Founder and CEO. | Reveal Email/Phone |
2 | COO | Reveal Email/Phone |
3 | Head Research And Development | Reveal Email/Phone |
4 | Group Leader, Stem Cell Biology | Reveal Email/Phone |
5 | Research Scientist | Reveal Email/Phone |
6 | Stem Cell Research Scientist | Reveal Email/Phone |
Minerva Biotechnologies Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Minerva Biotechnologies?
Minerva Biotechnologies is developing therapies for curing cancers and commercializing core technology that will enable next generation stem cell therapies. Both flow from Minerva's fundamental discovery that both cancer cell and stem cell growth are mediated by the same two molecules: the growth factor NME-p and the growth factor receptor MUC1*. -Cancer Therapeutics- Minerva discovered that cancer cells are healthy cells that are being reprogrammed back to a stem cell state. We can reverse the reprogramming and make cancer cells differentiate so that cancer growth is turned off. This is a novel approach to curing cancer. We have 3 anti-cancer therapeutics in our pipeline. -Regenerative Medicine- Minerva is the first company to generate human naïve state pluripotent stem cells using a single, naturally occurring human stem cell growth factor. These earlier stem cells have a clean slate, and are more easily directed to develop into functional mature cells, which could be used for transplant.
keywords:N/AN/A
Total Funding
27
Number of Employees
$4.2M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Minerva Biotechnologies News
Minerva Biotechnologies Corp; Transgene SA; Vaxil Bio Therapeutics Ltd. The region included in the report: North America (United States, Canada,...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $2.7M | 27 | 13% | N/A |
#2 | $2.7M | 27 | 0% | N/A |
#3 | $2.6M | 27 | N/A | N/A |
#4 | $4.4M | 28 | 8% | N/A |
#5 | $5.3M | 28 | 0% | N/A |